Preview complete
The prescreener preview is complete. You may now close the preview.
Check your eligibility now & get in touch with a study center text
CHECK ELIGIBILITYyyDetailed Description
Treatment options for acne conglobata are limited and those which are effective can only be used in short term such as systemic steroids, antibiotics or retinoids due to their association to side effects or potentially teratogenetic effects.
Apremilast, a specific inhibitor for PDE-4, mediates its clinical effect through the cAMP-PKA-NFkappaB pathway which results in a decrease of pro-inflammatory and increase of anti-inflammatory cytokines in several types of leukocytes. The clinical picture changes to a decrease of all signs of inflammation.
Due to the NFkappaB mediated chronical inflammation in the pathogenesis of acne conglobata, a treatment with Apremilast seems to be an effective option.
In this study, treatment with Apremilast (Otezla®) will be performed in patients with acne conglobata to observe its preliminary efficacy and safety in an open label, single-centre proof of concept study design.
Simple Text Block
You can use content blocks to arrange your articles, large texts, instructions. Combine these blocks with media blocks to add illustrations and video tutorials. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links.
Call 1800-9860-568 now to find out if you are eligible.
Check your eligibility
Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study. If you have the common symptoms, you may be eligible to take part in the study.
Age
0 - 100
Gender
Male
NCT ID
TX12713
Phase
-1
Status
Recruiting Now
Medical Condition
acne
How is Plaque Psoriasis treated?
Medical Condition
A short sentence to introduce what to expect in the about condition section
Learn moreThe Study
A short sentence to introduce what to expect in the about condition section
Learn moreAbout Clinical Trials
A short sentence to introduce what to expect in the about condition section
Learn moreYour Journey
01
Receiving the medication
You would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.
02
Visiting the study site
Study participation involves approximately 8 visits to your local study center over 6 to 7 months.
03
Follow-up
There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.